Results 41 to 50 of about 58,972 (283)

Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis

BMC Gastroenterology, 2022
Background and aims There are limited comparative data for infliximab and vedolizumab in inflammatory bowel disease patients. Methods We conducted a systematic review and meta-analysis to compare the efficacy and safety of infliximab and vedolizumab in ...
Laurent Peyrin-Biroulet, Perttu Arkkila, Alessandro Armuzzi, Silvio Danese, Jordi Guardiola, Jørgen Jahnsen, Charles Lees, Edouard Louis, Milan Lukáš, Walter Reinisch, Xavier Roblin, Minyoung Jang, Han Geul Byun, Dong-Hyeon Kim, Sung Jeong Lee, Raja Atreya   +15 more
doaj   +1 more source

External Model Performance Evaluation of Twelve Infliximab Population Pharmacokinetic Models in Patients with Inflammatory Bowel Disease

Pharmaceutics, 2021
Infliximab is approved for treatment of various chronic inflammatory diseases including inflammatory bowel disease (IBD). However, high variability in infliximab trough levels has been associated with diverse response rates.
Christina Schräpel, Lukas Kovar, Dominik Selzer, Ute Hofmann, Florian Tran, Walter Reinisch, Matthias Schwab, Thorsten Lehr   +7 more
doaj   +1 more source

Combination Immunotherapy as a Promising Strategy to Overcome Immunotherapy Resistance: From Emergence to Next‐Generation Approaches

Advanced Science, EarlyView.
This review examines emerging combination immunotherapy strategies tailored to distinct tumor microenvironments and highlights next‐generation biomarkers that guide response prediction and treatment personalization. It integrates lessons from unsuccessful trials, addresses toxicity challenges, and outlines approaches for early biomarker discovery and ...
Asmita Pandey, Sudhir Kumar Rai, Li Ma, Lauren Higa, Vedbar Khadka, Hua Yang, Youping Deng   +6 more
wiley   +1 more source

Body mass index influences infliximab post-infusion levels and correlates with prospective loss of response to the drug in a cohort of inflammatory bowel disease patients under maintenance therapy with Infliximab. [PDF]

PLoS ONE, 2017
Infliximab is an effective treatment for inflammatory bowel disease (IBD). Studies differ regarding the influence of body mass index (BMI) on the response to infliximab, with the majority of studies indicating that increased BMI may be associated with a ...
Franco Scaldaferri, Daria D'Ambrosio, Grainne Holleran, Andrea Poscia, Valentina Petito, Loris Lopetuso, Cristina Graziani, Lucrezia Laterza, Maria Teresa Pistone, Silvia Pecere, Diego Currò, Eleonora Gaetani, Alessandro Armuzzi, Alfredo Papa, Giovanni Cammarota, Antonio Gasbarrini   +15 more
doaj   +1 more source

Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis [PDF]

, 2023
Objective: We aimed to assess whether the introduction of the first infliximab biosimilar was associated with changes in overall infliximab consumption (originator and biosimilars) and price changes to the originator infliximab.Methods: An interrupted ...
Peng, K, Lau, CS, Cheng, F.W.T., Lai, ECC, Shin, JY, Pratt, N.L., Ward, M, Shin, J.Y., Hillen, J.B., Tong, XN, Yeung, WWY, Cheng, FWT, Blais, J.E., Stanford, T, Hillen, JB, Blais, JE, Guo, JJ, Wu, J, Leung, WK, Stanford, T., Lau, C.S., Leung, W.K., Li, X., Lai, E.C.C., Wu, J., Wong, I.C.K., Peng, K., Guo, J.J., Ward, M., Fan, M., Tong, X., Li, X, Yeung, W.W.Y., Fan, M, Wong, ICK, Pratt, NL   +35 more
core   +1 more source

Epithelial TRIM27 Inhibits Intestinal Inflammation in Ulcerative Colitis by the USP7/TRIM27‐IKK Double Negative‐Feedback

Advanced Science, EarlyView.
ABSTRACT The E3 ubiquitin ligase tripartite motif 27 (TRIM27) is a negative regulator of NF‐κB activation and the innate immune response, and TRIM27 deficiency significantly impairs dextran sulfate sodium (DSS)‐induced colitis. The function of TRIM27 in intestinal epithelial cells (IECs), the mechanism by which TRIM27 inhibits the NF‐κB pathway and its
Weimin Xu, Zhebin Hua, Zhujiang Dai, Shasha Zhang, Yihan Jiang, Wensong Ge, YingWei Chen, Zhongchuan Wang, Bing Zhang, Chen‐Ying Liu, Peng Du   +10 more
wiley   +1 more source

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

, 2022
Hepatology, EarlyView.
Robert J. Fontana, Iris Liou, Adrian Reuben, Ayako Suzuki, M. Isabel Fiel, William Lee, Victor Navarro   +6 more
wiley   +1 more source

Switching from Dose-Intensified intravenous to SubCutaneoUS infliximab in Inflammatory Bowel Disease (DISCUS-IBD): protocol for a multicentre randomised controlled trial

BMJ Open
Introduction A substantial proportion of patients with inflammatory bowel disease (IBD) on intravenous infliximab require dose intensification. Accessing additional intravenous infliximab is labour-intensive and expensive, depending on insurance and ...
Jonathan P Segal, Mayur Garg, Miles P Sparrow, Gareth J Walker, Ashish Srinivasan, Peter De Cruz, Desmond Chee, Alex Boussioutas, Robert V Bryant, Georgina Hold, Gregory T Moore, Susan J Connor, Robert D Little, Mark G Ward, Jo McKenzie, Patrick Hilley, Robert B Gilmore, Manjeet Sandhu, Daniel Saitta, Elizabeth Chow, Lena Thin, Kate Lynch, Jane Andrews, Yoon K An, Emily K Wright   +24 more
doaj   +1 more source

Long‐Term Outcomes After Stoma Creation in Crohn's Disease: A Retrospective Cohort Study of 422 Patients

Annals of Gastroenterological Surgery, EarlyView.
ABSTRACT Aim Stoma creation is often required in Crohn's disease (CD), most commonly because of progressive anorectal disease. As stoma closure strongly influences long‐term quality of life and surgical decision‐making, this study evaluated the indications and long‐term outcomes of stoma creation in patients with CD.
Kentaro Nagano, Ryuichi Kuwahara, Yusuke Tomoo, Kurando Kusunoki, Yuki Horio, Kei Kimura, Kozo Kataoka, Masataka Ikeda, Motoi Uchino, Hiroki Ikeuchi   +9 more
wiley   +1 more source

Lymphocyte‐C‐Reactive Protein Ratio as Promising New Marker for Predicting Surgical Site Infection in Children With Ulcerative Colitis

Annals of Gastroenterological Surgery, EarlyView.
ABSTRACT Background Surgical site infection (SSI) is a major complication after ileal pouch–anal anastomosis (IPAA) in pediatric ulcerative colitis (UC), significantly impairing quality of life. The lymphocyte‐to–C‐reactive protein ratio (LCR), a composite marker of systemic inflammation and immune/nutritional status, has emerged as a potential ...
Yuhki Koike, Koki Higashi, Yuki Sato, Yuka Nagano, Tadanobu Shimura, Takahito Kitajima, Kohei Matsushita, Yoshiki Okita, Yoshinaga Okugawa, Yuji Toiyama   +9 more
wiley   +1 more source